Bioventix (LSE:BVXP) EBIT: £9.77 Mil (TTM As of Dec. 2025)


LSE:BVXP Bioventix PLC LSE:BVXP
62 GF Score
Price £16.75
GF Value £35.80
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioventix EBIT?

Bioventix LSE:BVXP 62 EBIT is £9.77 Mil as of Dec. 2025. GuruFocus rates LSE:BVXP with a GF Score™ of 62/100 and a GF Value™ of £35.80 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Bioventix's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was £4.72 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was £9.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioventix's annualized ROC % for the quarter that ended in Dec. 2025 was 112.07%. Bioventix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 306.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioventix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.89%.


Bioventix  (LSE:BVXP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioventix's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=9.43 * ( 1 - 25.27% )/( (6.838 + 5.738)/ 2 )
=7.047039/6.288
=112.07 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioventix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9.43/( ( (0.404 + max(0.43, 0)) + (0.411 + max(4.9, 0)) )/ 2 )
=9.43/( ( 0.834 + 5.311 )/ 2 )
=9.43/3.0725
=306.92 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.032 + 0.689 + 0.020999999999999) - (0.947 + 0 + 0.365)
=0.43

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.17 + 0.723 + 0) - (1.993 + 0 + 0)
=4.9

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioventix's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=9.774/82.213
=11.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventix EBIT Related Terms


Bioventix EBIT Historical Data

* Premium members only.

The historical data trend for Bioventix's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventix EBIT Chart

Bioventix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.12 9.28 10.07 10.63 10.07

Bioventix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 5.47 5.02 5.06 4.72

LSE:BVXP vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Bioventix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventix EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioventix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioventix's EV-to-EBIT falls into.


LSE:BVXP
62GF Score
Bioventix PLC LSE:BVXP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventix EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £9.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £9.77 Mil mean?
Bioventix (LSE:BVXP) has a EBIT of £9.77 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioventix.
Is Bioventix's EBIT too high?
Bioventix's current EBIT is £9.77 Mil. Overall, Bioventix has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioventix's EBIT compare to VRTX and REGN?
Bioventix's EBIT of £9.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bioventix. Bioventix's current EBIT is £9.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventix stock overvalued right now?
Based on GuruFocus' analysis, Bioventix (LSE:BVXP) is currently considered Significantly Undervalued. The stock's GF Value™ is £35.80, compared to a current price of £16.75 — trading 53.2% below its estimated fair value. The current EBIT is £9.77 Mil. Bioventix's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bioventix (LSE:BVXP), the current EBIT is £9.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventix (LSE:BVXP) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventix stock appears to be undervalued. The current stock price of £16.75 is trading 53.2% below its estimated GF Value™ of £35.80. GuruFocus considers Bioventix to be Significantly Undervalued.

Key valuation signals for LSE:BVXP:

  • EBIT: £9.77 Mil
  • GF Value™: £35.80 vs. price of £16.75 (53.2% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the LSE:BVXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bioventix Business Description

Other Exchanges 51B:Germany
Address 27-28 Eastcastle Street, London, GBR, W1W 8DH
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
62GF Score

Get the complete analysis for LSE:BVXP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£16.75
Price
£35.80
GF Value